Luminal A tumors have highly effective targeted therapies, e.g. hormonal agents (tamoxifen, aromatase inhibitors), whereas HER2+ breast cancers are treated with anti-HER2 antibodies or small molecule HER2-kinase inhibitors6. Here, ERBB2 is linked to luminal A breast carcinoma.